Agenus says expanded MSS mCRC cohort data to be presented at ESMO GI

Agenus (AGEN) announced caller information from its ongoing Phase 1 proceedings evaluating botensilimab and balstilimab successful patients with microsatellite unchangeable metastatic colorectal crab volition beryllium presented astatine the 2025 European Society for Medical Oncology Gastrointestinal Cancers Congress successful Barcelona, Spain. A poster presumption volition diagnostic updated findings from an expanded cohort of 123 patients, incorporating further participants and extended follow-up to further measure objective enactment of the combination, including durability of effect and wide survival, the institution noted.

Confident Investing Starts Here:

• Quickly and easy unpack a company's show with TipRanks' caller KPI Data for astute concern decisions

• Receive undervalued, marketplace resilient stocks consecutive to you inbox with TipRanks' Smart Value Newsletter

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See the apical stocks recommended by analysts >>

Read More connected AGEN:

Disclaimer & DisclosureReport an Issue

• Biotech Alert: Searches spiking for these stocks today

• Agenus terms people raised to $4 from $3 astatine Baird

• Agenus’s Regulatory and Clinical Developments Prompt Neutral Stance Amid Uncertain FDA Pathway

• Agenus Inc. Reports Q1 2025 Progress and Financials

• Agenus Inc. Earnings Call: Optimism Amid Challenges